版本:
中国

BRIEF-Jazz Pharmaceuticals reports psoitive data from phase 2/3 study of Xyrem

April 24 Jazz Pharmaceuticals Plc-

* Jazz Pharmaceuticals announces positive results from the phase 2/3 express study of xyrem in pediatric patients with narcolepsy with cataplexy

* Jazz Pharmaceuticals Plc - xyrem demonstrated statistically significant differences in primary and key secondary efficacy endpoints

* Jazz Pharmaceuticals - preliminary safety results consistent with results observed in xyrem studies in adults and xyrem post-marketing experience Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐